Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2

Michael J. Cork, Laurent Eckert, Eric L. Simpson, April Armstrong, Sébastien Barbarot, Luis Puig, Giampiero Girolomoni, Marjolein de Bruin-Weller, Andreas Wollenberg, Yoko Kataoka, Anita Remitz, Stefan Beissert, Vera Mastey, Marius Ardeleanu, Zhen Chen, Abhijit Gadkari, Jingdong Chao

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

Background: Atopic dermatitis (AD) profoundly affects quality of life (QoL). Dupilumab significantly improves clinical outcomes, is well tolerated, and approved to treat inadequately controlled moderate-to-severe AD in adults; however, its effect on patient-reported outcomes (PROs) is not fully characterized. Objective: To evaluate the impact of dupilumab on patient-reported AD symptoms and QoL. Methods: Pooled data were analyzed from two identically designed phase 3 studies, LIBERTY AD SOLO 1 (NCT02277743) and SOLO 2 (NCT02277769), assessing the following PROs: Peak Pruritus Numerical Rating Scale (NRS), Pruritus Categorical Scale, SCORing AD (SCORAD), Dermatology Life Quality Index (DLQI), Patient-Oriented Eczema Measure (POEM), Hospital Anxiety and Depression Scale (HADS), five-dimension EuroQoL questionnaire (EQ-5D), and patient-assessed disease status and treatment effectiveness. Results: Dupilumab rapidly improved (vs. placebo) Peak Pruritus NRS scores by day 2 (p <.05), anxiety and depression (HADS), and QoL (DLQI) by week 2, and maintained through week 16 (p <.0001). At week 16, more dupilumab-treated than placebo-treated patients reported improvement in SCORAD itch and sleep, and no pain/discomfort (EQ-5D) (p <.0001). Limitations: Cultural differences of translated PROs. Conclusion: Dupilumab had a significant, positive impact on AD symptoms, including itch, sleep, pain, anxiety and depression, and QoL in adults with moderate-to-severe AD.

Original languageEnglish (US)
Pages (from-to)606-614
Number of pages9
JournalJournal of Dermatological Treatment
Volume31
Issue number6
DOIs
StatePublished - Aug 17 2020

Keywords

  • Atopic dermatitis
  • dupilumab
  • patient-reported outcomes
  • quality of life

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2'. Together they form a unique fingerprint.

Cite this